Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Eliem Therapeutics stock
Learn how to easily invest in Eliem Therapeutics stock.
Eliem Therapeutics is a biotechnology business based in the US. Eliem Therapeutics shares (ELYM) are listed on the NASDAQ and all prices are listed in US Dollars. Eliem Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy Eliem Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – ELYM. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Commission-free trading
- Commission-free crypto
- No minimum account balance
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Eliem Therapeutics stock price (NASDAQ: ELYM)Use our graph to track the performance of ELYM stocks over time.
Eliem Therapeutics shares at a glance
|Latest market close||$3.62|
|52-week range||$2.36 - $11.51|
|50-day moving average||$3.07|
|200-day moving average||$3.64|
|Wall St. target price||$6.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.54|
Buy Eliem Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Eliem Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Eliem Therapeutics price performance over time
|1 week (2023-01-20)||-5.63%|
|1 month (2022-12-27)||39.92%|
|3 months (2022-10-27)||19.60%|
|6 months (2022-07-27)||20.40%|
|1 year (2022-01-27)||-55.86%|
|2 years (2021-01-23)||N/A|
|3 years (2020-01-23)||N/A|
|5 years (2018-01-23)||N/A|
Eliem Therapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-17.91%|
|Return on equity TTM||-30.88%|
|Market capitalisation||$103.3 million|
TTM: trailing 12 months
Eliem Therapeutics share dividends
We're not expecting Eliem Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
- Sanofi ADR (SNY.US) (3.59% forward annual dividend yield)
Eliem Therapeutics overview
Eliem Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. .
Frequently asked questionsWhat percentage of Eliem Therapeutics is owned by insiders or institutions?
Currently 25.652% of Eliem Therapeutics shares are held by insiders and 69.779% by institutions. How many people work for Eliem Therapeutics?
Latest data suggests 43 work at Eliem Therapeutics. When does the fiscal year end for Eliem Therapeutics?
Eliem Therapeutics's fiscal year ends in December. Where is Eliem Therapeutics based?
Eliem Therapeutics's address is: 23515 NE Novelty Hill Road, Redmond, WA, United States, 98053 What is Eliem Therapeutics's ISIN number?
Eliem Therapeutics's international securities identification number is: US28658R1068
More guides on Finder
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert